Company Overview - Insmed Incorporated is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for patients with serious diseases [4][5] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [4] - Insmed is recognized as one of the best employers in the biopharmaceutical industry, having been named the No. 1 Science Top Employer for four consecutive years [5] Upcoming Investor Conferences - Insmed will present at the Guggenheim's Inaugural Healthcare Innovation Conference in Boston on November 11, 2024, at 1:00 p.m. ET [1] - The company will also participate in the UBS Global Healthcare Conference in California on November 12, 2024, at 11:45 a.m. PT / 2:45 p.m. ET [2] - Additional presentations include the Wolfe Research Healthcare Conference in New York on November 20, 2024, at 8:00 a.m. ET and the Jefferies London Healthcare Conference on November 21, 2024, at 8:30 a.m. GT / 3:30 a.m. ET [2] Webcast Information - The events will be webcast live and accessible via the investor relations section of Insmed's website [3] - Webcasts will be archived for 30 days following the live events [3]

Insmed (INSM) reported a third-quarter 2024 loss of $1.27 per share, wider than the Zacks Consensus Estimate of a loss of $1.19. In the year-ago quarter, the company posted a loss of $1.11 per share.Insmed generated total revenues of $93.4 million during the quarter, up 18% year over year. Quarterly sales were in line with the Zacks Consensus Estimate.Shares of INSM were down more than 4% on Thursday likely due to the earnings miss.See the Zacks Earnings Calendar to stay ahead of market-making news.Year to ...

Core Insights - Insmed reported $93.43 million in revenue for Q3 2024, marking an 18.2% year-over-year increase, with an EPS of -$1.27 compared to -$1.10 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $93.31 million by 0.12%, while the EPS fell short of the consensus estimate of -$1.19 by 6.72% [1] Revenue Breakdown - Revenue from Japan was $20.98 million, below the estimated $24.10 million, but showed a year-over-year increase of 30.9% [3] - Revenue from Europe and the rest of the world reached $5.57 million, slightly above the $5.45 million estimate, reflecting a 45.3% year-over-year growth [3] - U.S. revenue was $66.87 million, surpassing the average estimate of $64.70 million, with a year-over-year increase of 13% [3] Stock Performance - Insmed's shares have declined by 3.7% over the past month, contrasting with a 1% increase in the Zacks S&P 500 composite [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]

Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.72%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.22 per share when it actually produced a loss of $1.94, delivering a ...

Exhibit 99.1 1 Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025— —Expanded U.S. Sales Force is Now Fully Deployed; Focusing on Bronchiectasis Disease-State Awa ...

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023——NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025——Expanded U.S. Sales Force is Now Fully Deployed; Focusing on Bronchiectasis Disease-State Awareness and Supporting the Growth of ARIKAYCE Prior to the Anticipated Launch of Brensocatib——Ends ...

Wall Street analysts forecast that Insmed (INSM) will report quarterly loss of $1.19 per share in its upcoming release, pointing to a year-over-year decline of 8.2%. It is anticipated that revenues will amount to $93.31 million, exhibiting an increase of 18% compared to the year-ago quarter. The consensus EPS estimate for the quarter has undergone an upward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their ini ...

Company-wide day of service brings together more than 1,000 employees to support over 40 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Oct. 23, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today holds its third annual Global Day of Good, with more than 1,000 employees volunteering simultaneously in their respe ...

BRIDGEWATER, N.J., Oct. 17, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its third-quarter 2024 financial results on Thursday, October 31, 2024. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, October 31, 2024, to discuss the financial results and p ...

—Data Presented at the CHEST 2024 Annual Meeting— BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib ...